[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Inhibrx Biosciences Inc (INBX)

Inhibrx Biosciences Inc (INBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,681,120
  • Shares Outstanding, K 14,607
  • Annual Sales, $ 1,300 K
  • Annual Income, $ -140,060 K
  • EBIT $ -179 M
  • EBITDA $ -176 M
  • 60-Month Beta 1.82
  • Price/Sales 944.74
  • Price/Cash Flow N/A
  • Price/Book 152.99

Options Overview Details

View History
  • Implied Volatility 150.69% (+5.46%)
  • Historical Volatility 121.59%
  • IV Percentile 87%
  • IV Rank 25.22%
  • IV High 373.04% on 10/22/25
  • IV Low 75.69% on 01/30/26
  • Expected Move (DTE 22) 33.75 (28.14%)
  • Put/Call Vol Ratio 0.23
  • Today's Volume 403
  • Volume Avg (30-Day) 236
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 5,958
  • Open Int (30-Day) 5,723
  • Expected Range 86.19 to 153.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-2.37
  • Number of Estimates 1
  • High Estimate $-2.37
  • Low Estimate $-2.37
  • Prior Year $-2.80
  • Growth Rate Est. (year over year) +15.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
57.30 +109.30%
on 03/27/26
155.29 -22.77%
on 04/22/26
+55.30 (+85.56%)
since 03/23/26
3-Month
57.30 +109.30%
on 03/27/26
155.29 -22.77%
on 04/22/26
+45.27 (+60.63%)
since 01/23/26
52-Week
10.84 +1,006.37%
on 05/14/25
155.29 -22.77%
on 04/22/26
+107.77 (+886.27%)
since 04/23/25

Most Recent Stories

More News
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

SAN DIEGO , April 21, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic...

INBX : 119.93 (+4.21%)
Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

– Event to be webcast live on Tuesday, April 21, 2026, at 1:30 p.m. PT –

INBX : 119.93 (+4.21%)
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

SAN DIEGO , March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2025. Following...

INBX : 119.93 (+4.21%)
Inhibrx Announces Participation in Upcoming Scientific Conference

SAN DIEGO , March 2, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic...

INBX : 119.93 (+4.21%)
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

SAN DIEGO , Dec. 16, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for...

INBX : 119.93 (+4.21%)
Inhibrx Reports Third Quarter 2025 Financial Results

SAN DIEGO , Nov. 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the third quarter of 2025. Following the completion...

INBX : 119.93 (+4.21%)
Inhibrx Announces Participation in Upcoming Scientific Conferences

SAN DIEGO , Nov. 4, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic...

INBX : 119.93 (+4.21%)
Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

SAN DIEGO , Oct. 23, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for...

INBX : 119.93 (+4.21%)
Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

– Event to be webcast live on Thursday, October 23, 2025 at 1:30 p.m. PT –

INBX : 119.93 (+4.21%)
Inhibrx Reports Second Quarter 2025 Financial Results

SAN DIEGO , Aug. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2025. Following...

INBX : 119.93 (+4.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 80%. The market has entered extreme overbought territory.

See More Share

Business Summary

Inhibrx Inc. is a clinical-stage biopharmaceutical company. It focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 202.21
2nd Resistance Point 178.75
1st Resistance Point 146.92
Last Price 119.93
1st Support Level 91.63
2nd Support Level 68.17
3rd Support Level 36.34

See More

52-Week High 155.29
Last Price 119.93
Fibonacci 61.8% 100.11
Fibonacci 50% 83.06
Fibonacci 38.2% 66.02
52-Week Low 10.84

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.